Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Johari doha, Fariba, Rahmani, Siyavash, Rikhtechi, Pedram, Rasaneh, Samira, Sheikholislam, Zahra, Shahhosseini, Soraya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603870/
https://www.ncbi.nlm.nih.gov/pubmed/28979315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603870/
https://www.ncbi.nlm.nih.gov/pubmed/28979315

Ejemplares similares